Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 9

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 9
---
 a whole. In particular, your attention is drawn to paragraph 4 ( Action to be taken in relation to the General Meeting ) of Part II ( Explanation of the proposals to implement the Harmonised Listing Structure ) of this document and the part of this document headed “Action to be taken”.

The Directors consider the proposed Harmonised Listing Structure to be in the best interests of AstraZeneca and its Shareholders as a whole. Accordingly, the Directors unanimously recommend that Shareholders vote in favour of the Resolution to be proposed at the General Meeting, as the Directors intend to do in respect of their own beneficial holdings of AstraZeneca Shares.

Yours faithfully,

Michel Demaré 
 Chair 
 AstraZeneca PLC

<div align='center'>8</div>

TABLE OF CONTENTS

### PART IIEXPLANATION OF THE PROPOSALS TO IMPLEMENT THE HARMONISED LISTINGSTRUCTURE
**Your attention is drawn to the letter from the Chair of AstraZeneca set out in Part I ( Letter from the Chair of AstraZeneca PLC ) of this document. That letter contains, inter alia , the background to and reasons for the proposed Harmonised Listing Structure and the unanimous recommendation by the Board to Shareholders to vote in favour of the Resolution to be proposed at the forthcoming General Meeting, notice of which is included in Part VII ( Notice of General Meeting ) of this document.

That letter also states that the Board considers the proposal and its terms to be in the best interests of AstraZeneca and its Shareholders as a whole.

A description of the action to be taken by Shareholders in relation to the General Meeting is set out in the part of this document entitled “Action to be taken”. The full text of the Resolution to be proposed at the General Meeting is set out in Part VII (**

#### Notice of General Meeting

#### ) of this document.

#### 1.
**Summary of principal steps required to effect the Harmonised Listing Structure**

As set out in the letter from the Chair set out in Part I ( Letter from the Chair of AstraZeneca PLC ) of this document, implementation of the Harmonised Listing Structure requires the termination of the existing ADR Programme and migration of the primary settlement system applicable to the AstraZeneca Shares from CREST to DTC (the

#### “Settlement System Migration”
**).

•

Termination of ADR Programme: the existing ADR Programme and the current listing of AstraZeneca ADSs on Nasdaq will be terminated and the